Y Loriot

ALBAN (GETUG-AFU 37): a phase III, gerandomiseerde, open-label international trial of intravenous atezolizumab and in...

Annals of oncology : official journal of the European Society for Medical Oncology · 1 januari 2026

Enfortumab vedotin plus pembrolizumab in untreated locally gevorderd or metastatic urothelial carcinoma: 2.5-year med...

Annals of oncology : official journal of the European Society for Medical Oncology · 1 oktober 2025

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 tr...

Annals of oncology : official journal of the European Society for Medical Oncology · 1 september 2025

Sacituzumab govitecan in gevorderd urothelial carcinoma: TROPiCS-04, a phase III gerandomiseerde trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 1 mei 2025

Eerstelijns bij gevorderd urotheelcarcinoom: ESMO 2024 interim richtlijn update

Annals of oncology : official journal of the European Society for Medical Oncology · 1 juni 2024

Erdafitinib bij BCG-voorbehandeld hoogrisico blaascarcinoom

Annals of oncology : official journal of the European Society for Medical Oncology · 1 januari 2024

Erdafitinib versus pembrolizumab bij eerder behandeld FGFR-gealterd urotheelcarcinoom: THOR langetermijn

Annals of oncology : official journal of the European Society for Medical Oncology · 1 januari 2024

Enfortumab vedotin versus chemotherapie bij urotheelcarcinoom: EV-301 24-maanden

Annals of oncology : official journal of the European Society for Medical Oncology · 1 november 2023

Blaascarcinoom: ESMO 2022 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 1 maart 2022

Recidiefpatronen bij slechte-prognose kiemceltumoren in de GETUG 13 studie

European journal of cancer (Oxford, England : 1990) · 1 december 2017

Publicaties op Oncologisch.com